Active substance
Results for the substance efavirenz+emtricitabine+tenofovir
1 result
About this active substance
The combination of Efavirenz + Emtricitabine + Tenofovir is used for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents. It combines a non-nucleoside reverse transcriptase inhibitor (efavirenz) with two nucleoside reverse transcriptase inhibitors (emtricitabine and tenofovir) to suppress viral replication.
The medication is taken orally, usually once daily, and is effective in reducing viral load and increasing CD4 cell counts. It is used as part of combination antiretroviral therapy.
Side effects may include nausea, dizziness, insomnia, rash, and, in rare cases, liver or kidney impairment. Regular monitoring of liver and kidney function is essential.
Consult your doctor to discuss the benefits and risks of treatment with this combination. Follow the prescribed dosage and adhere to all medical recommendations.
The medication is taken orally, usually once daily, and is effective in reducing viral load and increasing CD4 cell counts. It is used as part of combination antiretroviral therapy.
Side effects may include nausea, dizziness, insomnia, rash, and, in rare cases, liver or kidney impairment. Regular monitoring of liver and kidney function is essential.
Consult your doctor to discuss the benefits and risks of treatment with this combination. Follow the prescribed dosage and adhere to all medical recommendations.